Significance of 18 F-FDG PET and immunohistochemical GLUT-1 expression for cardiac myxoma
© Okazaki et al.; licensee BioMed Central Ltd. 2014
Received: 28 March 2014
Accepted: 21 May 2014
Published: 16 June 2014
Cardiac tumours are relatively rare and are difficult to diagnose merely with imaging techniques. We demonstrated an unusual case of left atrial myxoma, displaying the successful detection by positron emission tomography using 2-deoxy-2-[18 F] fluoro-D-glucose (18 F-FDG PET), correlated closely to more intense and enhanced immunoreactivity with glucose transporter-1 (GLUT-1) in a substantial number of cardiac myxoma cells. Further prospective studies are needed to validate the significance of 18 F-FDG PET findings for cardiac myxoma and the association with immunohistochemical GLUT-1 expression in its tumour cells, after collecting and investigating a larger number of surgical cases examined with both of them.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2991481941253449
KeywordsCardiac myxoma 18 F-FDG PET Immunohistochemistry GLUT-1
Letter to the editor
The imaging technique of positron emission tomography with 2-deoxy-2-[18 F] fluoro-D-glucose (18 F-FDG PET) is based on the early observations by Warburg, that neoplastic (especially, malignant) cells accumulate more glucose than non-neoplastic cells do, as a result of high rate of glycolytic catabolism rather than citric acid cycle catabolism . 18 F-FDG PET has thus been increasingly performed in the diagnosis, pre-operative cancer staging, or follow-up post-treatment examination of many types of malignancy, whereas few studies have been reported regarding the utility of 18 F-FDG PET in intracardiac tumours [2–4]. Herein we reported an unusual case of left atrial myxoma, showing the successful detection by its technique, correlated closely to greater immunoreactivity with glucose transporter-1 (GLUT-1) in a larger number of cardiac myxoma cells.
Indeed, myxomas, as many as 60% of relatively rare cardiac tumours, could be considered to be common diseases, compared with some recently published papers of very unusual tumour cell types or features in the heart [2, 6]. Despite that, merely three case reports of atrial myxoma have demonstrated its appearance and utility in 18 F-FDG PET, revealing a moderately elevated glucose metabolism, very similar to our case, and likely assuming an established position in the routine clinical evaluation of cardiac tumours [2–4]. Furthermore, we describe the present unusual case, since it is conceivable that the current short report of cardiac myxoma located on the left atrium is clinicopathologically remarkable for another reason at least. A higher 18 F-FDG uptake rate in the present case could have a close correlation with a more specific and greater immunohistochemical expression of GLUT-1 in the myxoma cells, corresponding to the malignant cells in intraductal papillary mucinous neoplasms of the pancreas, as previously reported . Enhanced expression of GLUT-1 has actually been recognized in various cancer tissues examined, since one of the pivotal functions of ubiquitous GLUT-1 is known to particularly increase the glucose supply to dividing and growing cells in part, among a family of GLUT transporters [8, 9], possibly unlike these benign myxoma cells with relatively low MIB-1 index. However, the potential biological roles of accelerated glucose utilization in neoplastic cells still remain to be elucidated in detail. Nevertheless, it would be intriguing to assess the significance of 18 F-FDG PET findings for cardiac myxoma and the association with immunohistochemical GLUT-1 expression in the myxoma cells on future larger studies. The present short case report could interest the scientific community, taken together with potentially new and specific clinicopathological findings.
Written informed consent was obtained from the patient for the publication of this report and any accompanying images.
- Warburg O: On the origin of cancer cells. Science. 1956, 123: 309-314. 10.1126/science.123.3191.309.PubMedView Article
- Agostini D, Babatasi G, Galateau F, Grollier G, Potier JC, Bouvard G: Detection of cardiac myxoma by F-18 FDG PET. Clin Nucl Med. 1999, 24: 159-160. 10.1097/00003072-199903000-00003.PubMedView Article
- Gheysens O, Cornillie J, Voigt JU, Bogaert J, Westhovens R: Left atrial myxoma on FDG-PET/CT. Clin Nucl Med. 2013, 38: e421-e422. 10.1097/RLU.0b013e31827086a3.PubMedView Article
- Johnson TR, Becker CR, Wintersperger BJ, Herzog P, Lenhard MS, Reiser MF: Images in cardiovascular medicine. Detection of cardiac metastasis by positron-emission tomography-computed tomography. Circ. 2005, 112: e61-e62. 10.1161/CIRCULATIONAHA.104.488775.View Article
- Yamada S, Kitada S, Nabeshima A, Noguchi H, Sasaguri Y, Hisaoka M: Benign cutaneous plexiform hybrid tumor of perineurioma and cellular neurothekeoma arising from the nose. Diagn Pathol. 2013, 8: 165-10.1186/1746-1596-8-165.PubMedPubMed CentralView Article
- Neri M, Di Donato S, Maglietta R, Pomara C, Riezzo I, Turillazzi E, Fineschi V: Sudden death as presenting symptom caused by cardiac primary multicentric left ventricle rhabdomyoma, in an 11-month-old baby. Diagn Pathol. 2012, 7: 169-10.1186/1746-1596-7-169.PubMedPubMed CentralView Article
- Fassan M, Pizzi S, Sperti C, Pasquali C, Pedrazzoli S, Chierichetti F, Parenti AR: 18 F -FDG PET findings and GLUT-1 expression in IPMNs of the pancreas. J Nucl Med. 2008, 49: 2070-10.2967/jnumed.108.054924.PubMedView Article
- Mueckler M: Facilitative glucose transporters. Eur J Biochem. 1994, 219: 713-725. 10.1111/j.1432-1033.1994.tb18550.x.PubMedView Article
- Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, Yasuda S: Significance of 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol. 2002, 9: 15-18. 10.1046/j.1442-2042.2002.00416.x.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.